Increased lipid levels improves after treatment with Cabergolin in patients with Prolactinoma

Basit Öğe Kaydı
dc.contributor.authorTuna, Mazhar Müslüm
dc.contributor.authorNavdar Başaran, Mehtap
dc.contributor.authorArduç, Ayşe
dc.contributor.authorAyçiçek Doğan, Berçem
dc.contributor.authorBerker, Dilek
dc.contributor.authorGüler, Serdar
dc.date.accessioned2019-11-01T07:27:44Z
dc.date.available2019-11-01T07:27:44Z
dc.date.issued2015en_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.descriptionresearch
dc.description.abstractIt has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity. The study was aimed to investigate lipid abnormalities and androgen hormone levels before and after cabergolin (CAB) treatment in non- obese premenauposal patients with prolactinoma. This study was a single-centre, prospective, case-control study, consisted of 53 patients with symptomatic prolactinoma (group 1) and 57 healty women (group 3). All subjects underwent a physical examination, anthropometric measurement and a 12 hour fasting blood sample for fasting blood glucose and lipid levels. 49 patients with prolactinoma were reevaluated for metabolic parameters after one year of cabergolin treatment (group 2). The median age was 34 in group 1, and 33 in group 3 (p=0.522). The initially higher body mass index (BMI) in patients with prolactinoma became similar after one year of treatment those with control group (p=0.475). While LDL-C was significanly higher in group 1 than in controls, HDL was significanly lower in group 1. Also post- treatment values of LDL-C (p=0.440) and HDL-C (p=0.612) were not different from the control group. No correlation was found between baseline prolactin levels and FSH, LH, LDL-C, HDL-C (p=0.129, p=0.658, p=0.817, p=0.760 respectively). In conclusion, beneficial metabolic changes were seen in patients with prolactinoma after treatment with cabergoline. Thus considering the metabolic profile and an appropriate treatment goal is important in the clinical management of patients with prolactinoma.
dc.identifier.citationTuna, M. M., Dogan, B. A., Basaran, M. N., Arduc, A., Berker, D., Guler, S. (2015). Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma. Medicine Science, 4(1), 1985-1992.
dc.identifier.doi10.5455/medscience.2014.03.8196
dc.identifier.endpage1992en_US
dc.identifier.issn2147-0634
dc.identifier.issue1en_US
dc.identifier.startpage1985en_US
dc.identifier.urihttps://hdl.handle.net/11491/4882
dc.identifier.volume4en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofMedicine Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAndrogen Hormonesen_US
dc.subjectLipid Abnormalitiesen_US
dc.subjectHyperprolactinemiaen_US
dc.subjectProlactinomaen_US
dc.titleIncreased lipid levels improves after treatment with Cabergolin in patients with Prolactinoma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
serdar-guler2015.pdf
Boyut:
465.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu